Biomarker, molecular probe and kit for detecting prostatic cancer

• Main Authors: WANG LEI, TANG MEIYUN, DING ZHIYAN
• Format: Patent
• Language: Chinese; English
• Published: 13.02.2024
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; COMPOSITIONS THEREOF; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; CULTURE MEDIA; ENZYMOLOGY; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PROCESSES OF PREPARING SUCH COMPOSITIONS; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPIRITS; VINEGAR; WINE

The invention relates to the technical field of molecular biological detection, in particular to a biomarker, a molecular probe and a kit for detecting prostatic cancer. The invention provides a biomarker for detecting prostatic cancer. The nucleotide sequence of the biomarker is as shown in SEQ ID NO. 1. According to the present invention, the proliferation level of the prostate cancer cells is evaluated by detecting the relative expression quantity of the Argonaute protein and the 3 'tRF-mtProTGG complex in the blood, and the 3' tRF-mtProTGG in the blood is easily degraded, such that the Argonaute protein and the 3 'tRF-mtProTGG complex are stable so as to further embody the biological effect of the Argonaute protein, and the present invention further provides the molecular probe, and the molecular probe has high sensitivity and high specificity. 本发明涉及分子生物学检测技术领域，尤其涉及一种检测前列腺癌的生物标志物、分子探针以及试剂盒。本发明提供了一种检测前列腺癌的生物标志物，所述生物标志物的核苷酸序列如SEQ ID NO.1所示。本发明是通过检测血液中Argonaute蛋白与3'tRF-mtProTGG复合体相对表达量，评判前列腺癌细胞的增殖水平。因血液中3'tR